Clinical Trials Logo

Edema clinical trials

View clinical trials related to Edema.

Filter by:

NCT ID: NCT03832179 Recruiting - Cataract Clinical Trials

Steroid vs. Anti-vascular Endothelial Growth Factor for Diabetic Macular Edema Prior to Phacoemulsification

STAMP
Start date: November 15, 2018
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to compare the efficacy of antecedent intravitreal anti-vascular endothelial growth factor therapy vs. Ozurdex in reducing post-cataract surgery related macular edema in patients with pre-existing diabetic macular edema.

NCT ID: NCT03821168 Recruiting - Clinical trials for Refractory Diabetic Macular Edema

The Effect of Intravitreal Erythropoietin Injection for Refractive Diabetic Macular Edema

Start date: March 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

after advent of RD photoreceptor degeneration Occurred. This process appears as a incredible and progressive event that will not stop till reattachment of RPE and neurosensory retina happened . Process of degeneration begins from first hours of RD establishment Neuroprotection of photoreceptor following RD is a novel and debatable discussion encountered in recent years . How to stop this phenomena and neuroprotective agent role in this issue are a new interest of researches. In the study investigators are planning to perform a clinical trial to demonstrate the minocycline neuroprotective effect in a double blind design as this impact has been implicated previously in a animal study.

NCT ID: NCT03784443 Withdrawn - Diabetes Clinical Trials

Combined Ranibizumab and Iluvien for Diabetic Macular Oedema

CASSIE
Start date: September 1, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

This trial investigated whether adding Iluvien sustained release steroid intravitreal eye implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor) intravitreal eye injection treatment for diabetic macular oedema would improve disease stability and reduce the need for regular anti-VEGF intravitreal eye injections over first two years. Diabetic macular oedema, accumulation of microscopic fluid at the back of the eye, is a major cause of poor vision in patients with diabetes. This is a double mask randomized control multisite trial, to be conducted at 10 NHS hospital eye clinics in England.

NCT ID: NCT03783832 Recruiting - Clinical trials for Diabetic Macular Edema

Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography

DOCTA
Start date: June 19, 2018
Phase:
Study type: Observational

This is a non-interventional, longitudinal, retrospective and prospective, non-controlled, single arm study in naive or non-naive patients with diabetic macular edema for which aflibercept (EYLEA®) therapy is indicated.

NCT ID: NCT03768752 Completed - Sepsis Clinical Trials

Diastolic Dysfunction and Interstitial Lung Edema in Septic Patients

Start date: October 11, 2018
Phase:
Study type: Observational

Sepsis is one of the most challenging conditions with an exceptionally high mortality rate. Diastolic Dysfunction is common in septic patients and has been found to be associated with mortality. However, the reasons for this remain unclear. Therefore, the goal of this study is to investigate diastolic dysfunction in septic patients on the intensive care unit. Special attention is paid to the presence of lung edema and general edema as a potential link between diastolic dysfunction and elevated mortality in septic patients. During the septic phase daily ultrasound examinations of heart and lung will be performed as to monitor diastolic function and lung edema.

NCT ID: NCT03762226 Recruiting - Clinical trials for Diabetic Macular Edema

Influence of Systemic Parameters in Diabetic Macular Edema - LIPSIA Study

Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study aims to evaluate the influence and prognostic value of systemic factors (such as the cardiovascular and metabolic status) on the treatment response to anti-VEGF therapy in macular edema due to diabetes or retinal vein occlusion.

NCT ID: NCT03759860 Active, not recruiting - Clinical trials for Diabetic Macular Edema

Laser (Selective Retina Therapy) and Drug Combined Intervention in Clinically Significant Diabetic Macular Edema

Start date: January 8, 2018
Phase: Phase 4
Study type: Interventional

The objective of this clinical trial is to compare and evaluate the safety and efficacy of Ranibizumab (Lucentis®; Novartis AG, Basel, Switzerland) monotherapy and Ranibizumab combined with R:GEN (Selective Retina Therapy) in patients with clinically significant diabetic macular edema.

NCT ID: NCT03751501 Not yet recruiting - Clinical trials for Diabetic Retinopathy

Targeted Laser in Diabetic Macular Edema

TaLa-DME
Start date: November 22, 2018
Phase: N/A
Study type: Interventional

Our hypothesis is that implementing laser photocoagulation (IGTL) as an adjunctive treatment to intravitreal injections should lead to a significant reduction in the need for intravitreal injections in patients with diabetic macular edema without adverse consequences for visual acuity.

NCT ID: NCT03739593 Completed - Macular Edema Clinical Trials

Study Assessing AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

Start date: March 13, 2019
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety, tolerability and efficacy of AR-1105 (dexamethasone implant) for the treatment of macular edema (ME) due to retinal vein occlusion (RVO). A more durable intravitreal implant containing a low dose of dexamethasone may result in less frequent retreatments, and potentially lower the incidence of steroid-related side effects without compromising efficacy.

NCT ID: NCT03715387 Recruiting - Edema Face Clinical Trials

Tacrolimus for Malar Edema

Start date: October 10, 2018
Phase: Phase 2/Phase 3
Study type: Interventional

Elective lower eyelid surgery is a common cosmetic procedure. Facial swelling is a common complication. Studies suggest that this facial swelling is part of a complex inflammatory process. Topical tacrolimus has long been used to treat various inflammatory skin disorders. By combining our knowledge of facial swelling and tacrolimus mechanism of action, we can hypothesize that it can be used as a treatment to prevent this post-operative swelling. The purpose of this project is to apply topical tacrolimus to one of the patient's cheeks following facial surgery and compare the incidence of facial swelling to the opposite side control cheek.